hematological-malignancies

Documents about hematological-malignancies

• M-2018-334 in Hematological Malignancies#867770ClinicalTrials.gov
• Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection#303716ClinicalTrials.gov
• Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects#865488ClinicalTrials.gov
• Exercise During Chemotherapy for Patients With Hematological Malignancies#876014ClinicalTrials.gov
• A Study of TQB3820 in Patients With Hematological Malignancies#812569ClinicalTrials.gov
• PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)#880495ClinicalTrials.gov
• Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B#181755ClinicalTrials.gov
• Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions#454029ClinicalTrials.gov
• A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies#916791ClinicalTrials.gov
• Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion#417535ClinicalTrials.gov
• Tissue Microarray of Hematological Malignancies#911988ClinicalTrials.gov
• Distraction With Virtual Reality From Pain and Anxiety for Patients With Hematological Malignancies#849050ClinicalTrials.gov
• Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells#471454ClinicalTrials.gov
• Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies#886860ClinicalTrials.gov
• Factors associated with treatment resumption and long-term outcomes after ICU discharge in patients with hematological malignancies#1000638HAL (France)
• Telomere and telomerase in hematological disorders Focusing on bone marrow failure syndromes and hematological malignancies#930385Acta Interna: The Journal of Internal Medicine
• Dual PD-1 and JAK2 Inhibition in Hematological Malignancies#828841ClinicalTrials.gov
• Trial of Pimasertib in Hematological Malignancies#877176ClinicalTrials.gov
• Detection of Bloodstream Pathogens in Hematological Malignancies#143588ClinicalTrials.gov
• Digital intrinsic capacity assessment of older patients with hematological malignancies: The ONCO-ICOPE cohort#126863HAL (France)
• Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT#872292ClinicalTrials.gov
• MS Detection of Somatic Mutations in Hematological Malignancies#879488ClinicalTrials.gov
• Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies#125824ClinicalTrials.gov
• COVID19-hematological Malignancies: the Italian Hematology Alliance#834692ClinicalTrials.gov
• Study of ABT-751 in Patients With Refractory Hematologic Malignancies#899636ClinicalTrials.gov
• Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors#474874ClinicalTrials.gov
• Assess the Oral Bioavailability of New ABT-263 Formulations#880350ClinicalTrials.gov
• CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS#195325ClinicalTrials.gov
• Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies#874809ClinicalTrials.gov
• Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan#804566ClinicalTrials.gov
• Pharmaceutical approval process of drugs for hematological malignancies: current situations in Japan#22603J-STAGE (Japan)
• Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence.#422929NCBI PubMed Central
• Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)#883917ClinicalTrials.gov
• CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.#160363ClinicalTrials.gov
• A Phase I Study of BR108 in Hematological Malignancies#802157ClinicalTrials.gov
• Remodeling the marrow fat niche: BMAT in cancer bone metastases and hematological malignancies.#297317NCBI PubMed Central
• Safety and Efficacy Evaluation of IM19 Cells#861689ClinicalTrials.gov
• Compassionate Use Study of Tenalisib (RP6530)#912687ClinicalTrials.gov
• Clinical decision support in hematological malignancies using a case-grounded AI agent.#988520NCBI PubMed Central
• Second primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management#120200Europe PMC
• Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies#901721ClinicalTrials.gov
• A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies#897857ClinicalTrials.gov
• Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?#89915PhilArchive
• 森林图合集：血液肿瘤患者并发肛周感染影响因素的Meta分析#420124Figshare
• Ruxolitinib and Decitabine for High Risk Hematological Malignancies#828895ClinicalTrials.gov
• Extracorporal Photopheresis Pilot Study#836881ClinicalTrials.gov
• CAR-T Cell Therapy in Patients With Hematological Malignancies#837549ClinicalTrials.gov
• A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies#981554ClinicalTrials.gov
• A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)#127628ClinicalTrials.gov
• Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies#394768ClinicalTrials.gov